Skip to main navigation

Skip to Content

Kinnate Investor Navigation

Overview
Press Releases
Events
Publications / Presentations
Financial Information
- SEC Filings
- Annual Reports
Corporate Governance
Stock Information
Investor Resources
- Investor FAQs
- Email Alerts
Media & IR Contact

Price
Change

stock chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Investor Tools

Press Releases

Year

Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences

Jun 01, 2023

Read More

Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates

May 11, 2023

Read More

Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance

Apr 17, 2023

Read More

First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma

Apr 17, 2023

Read More

Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates

Mar 15, 2023

Read More

Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting

Mar 14, 2023

Read More

Kinnate Biopharma Inc. Provides Statement on Silicon Valley Bank Receivership

Mar 12, 2023

Read More

Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China

Feb 21, 2023

Read More

Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor

Feb 14, 2023

Read More

Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference

Feb 06, 2023

Read More

Pagination

Current page 1
Page 2
Next page
Last page

Kinnate Footer Legal

Linkedin
Contact
Privacy
Terms of Use

© 2023 Kinnate Biopharma